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Available online 12 November 2015Oral absorption is a key element for safety assessments of cosmetic ingredients, including hair dye molecules.
Reliable in vitro methods are needed since the European Union has banned the use of animals for the testing
of cosmetic ingredients. Caco-2 cells were used to measure the intestinal permeability characteristics (Papp) of
14 aromatic amine hair dye molecules with varying chemical structures, and the data were compared with
historical in vivo oral absorption rat data. The majority of the hair dyes exhibited Papp values that indicated
good in vivo absorption. The moderate to high oral absorption ﬁndings, i.e. ≥60%, were conﬁrmed in in vivo rat
studies. Moreover, the compound with a very low Papp value (APB: 3-((9,10-dihydro-9,10-dioxo-4-
(methylamino)-1-anthracenyl)amino)-N,N-dimethyl-N-propyl-1-propanaminium) was poorly absorbed
in vivo as well (5% of the dose). This data set suggests that the Caco-2 cell model is a reliable in vitro tool for
the determination of the intestinal absorption of aromatic amines with diverse chemical structures. When
used in combination with other in vitro assays for metabolism and skin penetration, the Caco-2 model can
contribute to the prediction and mechanistic interpretation of the absorption, metabolism and elimination
properties of cosmetic ingredients without the use of animals.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Hair dyes1. Introduction
The safety assessment of hair dyes naturally involves the measure-
ment of dermal exposure since this route is the most relevant for
consumer exposure: a hair color formulation containing the dye mole-
cules is applied to the hair with access to the scalp for approximately
30 min and then washed off. However, knowledge of oral exposure is
also important because the oral route is a key requirement in safety
assessment in order to estimate systemic exposure with no effect levels
(i.e., NOELs). The traditional in vivomodel to analyze systemic exposure
involved oral, intravenous (i.v.) and dermal application of a compound
to the shaved skin of a rat, followed by measurement of plasmaro-6-ethylamino-4-nitrophenol;
6; HCR, HC Red no 13; HCY, HC
ole; ACP, 2-amino-6-chloro-4-
ino-m-cresol; AMP, 6-amino-m-
C, area under the curve; DMSO,
tion; HMA, hydroxyethyl-3,4-
amine; NOAEL, no adverse effect
Economic Co-operation and
ittee on Consumer Safety; TDA,
ce.
. This is an open access article underconcentrations and excretion in urine and feces of the parent compound
and itsmetabolites (OECD TG427, 2004). As part of the 7th Amendment
to the Cosmetics Directive of the European Union, these in vivo rodent
toxicokinetics studies were banned as of March, 2013 (EU, 2003).
Therefore, reliable in vitro methods are key tools helping to provide
information on absorption, metabolism and elimination needed to
conduct a safety assessment. We have integrated a toolbox of in vitro
models into our safety assessment strategy in order to predict skin ab-
sorption, as well as skin and hepatic metabolism properties of hair dye
ingredients (Manwaring et al., 2015). Our ﬁndings showed that the
combined use of in vitro absorption and metabolism assays using
ex vivo skin, keratinocytes and hepatocytes have correctly predicted
the toxicokinetic properties of a number of aromatic amine hair dye
ingredients. Carrying on from this work, we describe here how the
in vitro Caco-2model can be applied to predict the intestinal absorption
of aromatic amine hair dyes following oral exposure. When used in
combination, in vitro assays predicting dermal and oral absorption as
well as dermal and hepatic metabolism can provide a reliable basis to
estimate the systemic exposure of the parent compound. Furthermore,
the data can be particularly useful for read-across scenarios from a
data-rich compound to one with limited data.
Caco-2 cells originate from a human colon carcinoma and can differ-
entiate spontaneously into cells resembling mature small intestinalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2 C. Obringer et al. / Toxicology in Vitro 32 (2016) 1–7enterocytes. These cells express carrier proteins similar to the small in-
testine and, moreover, the TC-7 sub-clone has been shown to express
the apically-located efﬂux pump, P-glycoprotein (P-gp) (Raeissi et al.,
1999). Thismodel is widely used to predict the absorption across the in-
testinal barrier (Sambuy et al., 2005; Skolnik et al., 2010), and a good
correlation between oral drug absorption in humans and the apparent
drug permeability (Papp) across the in vitro Caco-2 cell barrier has
been shown (Artursson and Karlsson, 1991; Grès et al., 1998). This
in vitro model was also included in the report of the 46th ECVAM
workshop, identifying it as a suitable model for drug absorption (Le
Ferrec et al., 2001).
The validity and suitability of such assays are typically conﬁrmed by
reference compounds for high and low absorption. In these particular
studies, propranolol was used as a high permeability reference since
90% of the dose is absorbed in humans (Grès et al., 1998); and ranitidine
as a low permeability reference of which only 50% of the dose is
absorbed in humans. In the majority of the assays, a third reference
compound, namely vinblastine, was also included as a second lowFig. 1. Chemical structure of aromatic amine hair dye molecules similar to phenylenediamabsorption reference compound since its absorption is low and inﬂu-
enced by the presence of P-gp (Ogihara et al., 2006).
In this paper, we assess the applicability of the in vitro Caco-2 assay
for cosmetics ingredients by predicting the permeability characteristics
of 14 aromatic amine hair dye molecules related to phenylenediamine,
aminophenol and anthraquinone based on their comparison with
historical oral absorption data from rats (Fig. 1). The compounds chosen
were all hair dye ingredients for which historical in vivo data were
available.
2. Materials and methods
2.1. Chemicals
The hair dyes tested were TDA (toluene 2,5-diamine, CAS number
615-50-9); AMC (4-amino-m-cresol, CAS number 2835-99-6); AMP
(6-amino-m-cresol, CAS number 2835-98-5); HPD (hydroxyethyl-p-
phenylenediamine, CAS number 93841-25-9); HMA (hydroxyethyl-ine, aminophenol and anthraquinone. All structures are shown as the free base form.
Table 1
Apical to basolateral permeability of test chemicals in Caco-2 cells. Apparent permeability values (Papp) were measured for reference low (vinblastine and/or ranitidine) and high
(propranolol) absorption compounds, which were run at the same time as each test chemical. The values represent mean data (±SD) from two separate dosing solutions of each
compound tested in one experiment, each with 3 to 6 wells independently analyzed.
Test chemical Test chemical Papp (×10−6 cm/s) Low absorption control
Papp (×10−6 cm/s)
High absorption control
Papp (×10−6 cm/s)
% Absorbed test chemical
Papp/Propranolol Pappb
Vinblastine Ranitidine Propranolol
TDA 142.9 ± 41.5 0.06 ± 0.02 0.4 ± 0.0 47.8 ± 3.2 100 (high)
AMC 86.3 ± 38.6 0.05 ± 0.04 0.43 ± 0.04 29.6 ± 0.7 100 (high)
AMP 129.9 ± 2.2 0.05 ± 0.04 0.43 ± 0.04 29.6 ± 0.7 100 (high)
HPD 77.6 ± 20.9 0.25 ± 0.07 0.15 ± 0.07 53.1 ± 7.2 100 (high)
HMA 83.1 ± 5.7 0.49 ± 0.35 0.29 ± 0.15 34.2 ± 3.5 100 (high)
HCR 37.1 ± 2.9 0.07 ± 0.03 0.20 ± 0.00 25.9 ± 2.9 100 (high)
CEN 140.0 ± 7.5 0.06 ± 0.02 0.40 ± 0.05 47.8 ± 3.2 100 (high)
ACP 133.2 ± 0.4 0.06 ± 0.02 0.40 ± 0.05 47.8 ± 3.2 100 (high)
HAP 77.8 ± 4.1 0.07 ± 0.03 0.20 ± 0.00 25.9 ± 2.9 100 (high)
HCY 82.6 ± 5.8 0.33 ± 0.06 0.23 ± 0.04 58.3 ± 14.9 100 (high)
AHTa 28.2 ± 14.6 ND 1.44 ± 1.21 38.3 ± 1.7 97.5 (high)
HDAP 21.3 ± 2.1 0.49 ± 0.35 0.29 ± 0.15 34.2 ± 3.5 63.7 (moderate -high)
AEPa 8.9 ± 1.8 ND 1.44 ± 1.21 38.3 ± 1.7 23.3 (low–moderate)
APBa 1.7 ± 0.4 ND 1.44 ± 1.21 38.3 ± 1.7 3.7 (low)
Some compounds were tested in the same experiment. aapical pH was 7.4; babsorption category in parentheses; ND = not determined.
3C. Obringer et al. / Toxicology in Vitro 32 (2016) 1–73,4-methylenedioxyaniline, CAS number 94158-14-2); HCR (2,2′-((4-
amino-3-nitrophenyl)imino)bisethanol (HC red No. 13)), CAS number
94158-13-1); CEN (2-chloro-6-ethylamino-4-nitrophenol, CAS number
131657-78-8); ACP (2-amino-6-chloro-4-nitrophenol, CAS number
6358-09-4); HAP (4-hydroxypropylamino-3-nitrophenol, CAS number 92952-
81-3); HCY (1-(2-hydroxyethyl)amino-2-nitro-4-triﬂuormethylbenzene
(HC yellow No. 13), CAS number 10442-83-8); AHT (4-amino-2-
hydroxytoluene, CAS number 2835-95-2); HDAP (1-hydroxyethyl
4,5-diamino pyrazole, CAS number 155601-30-2); AEP (2-amino-
5-ethylphenol, CAS number 149861-22-3); and APB (3-((9,10-dihydro-
9,10-dioxo-4-(methylamino)-1-anthracenyl)amino)-N,N-dimethyl-N-pro-
pyl-1-propanaminium, CAS number 502453-61-4). HPD was fromMedPro
Vienna, Austria. All other hair dyes were from The Procter and Gamble
Service GmbH. Radiolabelled HMA was from BlyChem, Billingham,
UK; radiolabelled HCR andHAPwere from The Austrian Research Centre,
Institute of Chemistry, Seibersdorf, Germany; and radiolabelled CEN and
ACP were from Sigma Chemie, Deisenhofen, Germany. All other
radiolabelled compounds were from Amersham Biosciences, Bucking-
hamshire, UK. All other chemicalswere fromSigma-Aldrich orApplichem
GmbH, Gatersleben, Germany, and were of analytical grade. Structures
for the hair dyes are shown in Fig. 1. All hair dyes are referred to as theTable 2
Excretion of test chemicals in urine and feces after oral and i.v. administration. Calculation of th
amount recovered) and the normalized plasma AUC.
Test chemical Dose (mg/kg) % in urine % in feces
Oral i.v. Oral
TDA 2.5 62.2 ± 3.6 53.5 ± 6.3 31.4 ± 5.8
AMC 60 92.0 ± 3.5 87.8 ± 2.5 3.9 ± 0.1
AMP 25 91.3 ± 5.3 88.6 ± 2.6 4.7 ± 0.9
HPD 3 82.8 ± 2.7 ND 13.6 ± 3.0
HMA 1 77.8 ± 8.2 78.9 ± 12.6 14.3 ± 1.4
HCR 5 45.1 ± 7.5 ND 53.5 ± 7.0
CEN 5 62 ± 10 ND 31 ± 12
ACP 146 68.4 ± 4.5 ND 29.7 ± 4.6
HAP 0.02 67.5 ± 4.6 ND 29.3 ± 4.7
HCYb 5 82 ND 18
AHT 12.5 88.9 ± 1.3 93.8 ± 2.6 11.0 ± 1.2
HDAP 10 73.3 ± 8.3 86.9 ± 8.0 28.2 ± 2.3
AEP 370 (p.o.), 75 (i.v.) 82.9 ± 4.2 82.0 ± 3.2 10.8 ± 1.3
APB 100 (p.o.), 1 (i.v.) 0.9 ± 0.5 17.5 ± 2.7 87.0 ± 2.8
a 0.8 is with all animals and 10.9 is with values from two animals excluded because they sho
SCCS dossier; ND = not determined.free base form, as that is the biologically relevant entity and the form
present at the pH in the relevant product formulation.2.2. Caco-2 cell culture and incubations
The Caco-2 studies were performed by external contract labs
between November, 2003 and March, 2008. Caco-2 cells (sub-clones
TC 7 and HTB 37) from American Type Culture Collection (Manassas,
VA, USA) were seeded in 12-well or 96-well polyester Corning®
Costar® transwell plates (Sigma-Aldrich, St. Louis, MO, USA) in Caco-2
medium (Dulbecco's Modiﬁed Eagle Medium supplemented with 10%
fetal calf serum (Life Technologies, Darmstadt, Germany), 1% non-
essential amino acids (GE Healthcare Life Sciences, Pasching,
Germany) and 1% gentamycin (GE Healthcare Life Sciences)). The cells
were cultured for up to 25 days in a humidiﬁed incubator maintained
at 37 °C in an atmosphere of 5% CO2. The medium was renewed every
3 days. The monolayer integrity was checked every 3 days (at the time
of themedium change) bymeasuring the transepithelial electrical resis-
tance (TEER) until it reached a plateau of at least 280Ω cm2. On the day
of the study, after TEER measurement, the medium was removed ande % oral absorption (mean ± SD) from total radioactivity in the urine (normalized to the
Plasma dose normalized
AUC (h.mg/kg/mg.kg)
% Oral absorption
i.v. Oral i.v. Urine Plasma
27.3 ± 2.1 7.10 7.46 100 95
2.0 ± 0.3 2.92 3.49 98 84
4.8 ± 0.4 1.92 3.46 100 55
ND ND ND 86 ND
13.1 ± 4.4 8.70 9.55 99 91
ND ND ND 46 ND
ND ND ND 67 ND
ND ND ND 70 ND
ND ND ND 70 ND
ND ND ND 82 ND
5.7 ± 2.5 1.90 4.73 94 40
6.0 ± 2.6 2.23 3.25 77 69
10.6 ± 1.5 2.41 4.73 100 51
67.2 ± 4.1 0.06 8.0 5 0.8–10.9a
wed the highest concentrations compared to others in the same group; bdata taken from
Fig. 2. A comparison of the absorption of different hair dyes through Caco-2 monolayers
(A) and in vivo absorption in rats (B) using the oral and i.v. urine data. The in vitro values
are expressed as a percentage of propranolol absorption (a control for high absorption).
Papp values which were higher than the propranolol control values were set to 100% of
propranolol Papp.
4 C. Obringer et al. / Toxicology in Vitro 32 (2016) 1–7the cells were washed twice with pre-warmed (37 °C) Hank's Balanced
Salt Solution (HBSS, Sigma-Aldrich) buffer to remove traces of medium.
Stock solutions were made in dimethyl sulfoxide (DMSO) or water,
and further diluted in HBSS (ﬁnal DMSO concentration was 1%). Each
compound and reference compound (propranolol, ranitidine and/or
vinblastine dissolved in HBSS) was applied to the apical side of the
Caco-2 monolayer (all tested at a ﬁnal concentration of 50 μM). There
were two separate dosing solutions conducted for each compound,
eachwith 3 to 6wells independently analyzed. The pHvalues of the api-
cal and basolateral compartments were 6.5 and 7.4, respectively, with
the exception of AHT, AEP and APB, for which the apical pH was 7.4.
After 60 min, aliquots were taken from both the apical and basolateral
compartments. All samples were frozen in liquid nitrogen immediately
after removal and were stored at−20 °C until analysis.
To conﬁrm that the test chemicals did not compromise themonolay-
er integrity, which would cause the Papp value to be erroneously high,
the TEER was measured again after incubation with high, medium and
low absorption test chemicals (AHT, HDAP and APB, respectively).
None of the three dyes affected the TEER values (data not shown).
Likewise, 1% DMSO did not affect the TEER values in the monolayers
(data not shown).
After thawing at room temperature, the sampleswere centrifuged at
1000 ×g, and an aliquot (90 μl) of the supernatant of each sample was
transferred to a fresh analytical vial. The internal standard, chlorprop-
amide (10 μl 15.5 μg/ml in methanol), was then added. The samples
were thoroughly mixed before analysis by LC–MS/MS.
The concentration of each compound was determined in the apical
and basolateral compartments, converted to the amount in the
total volume and correlated to the surface area of the transwell (togive a value in μg/cm2). The Papp (cm/s) was determined using Eq. (1)
(Pardridge et al., 1990):
Papp ¼ dQdt 
1
m0
 1
A
 VDonor ð1Þ
dQ: amount of substance transported (nmol or μg); dt: incubation time
(3600 s);m0: amount of substrate applied to donor compartment (nmol
or μg); A: surface area of transwell membrane (cm2); VDonor: volume of
the donor compartment (cm3). To conﬁrm that the transwell mem-
branes had no inﬂuence on the Papp, negative controls without cells
were run in parallel.
The values represent mean data from two separate dosing solutions
of each compound tested in one experiment, each with 3 to 6 wells
independently analyzed. For comparative purposes, the test compound
Papp was divided by the corresponding propranolol Papp (in the same
study) to give a % absorbed. Test compound Papp values higher than that
of propranolol Papp values were set to a maximum of 100% (Table 1,
column 6).
2.3. In vivo absorption of compounds in the rat
All historical in vivo data are from studies conducted at external
contract labs between July 1988 and June 2009. All animals were
handled in accordance with Dutch and EU regulations, as well as EC
guidelines (EC, 1988). Animals were housed in a controlled environ-
ment at 21 ± 3 °C, 30–70% humidity and a light cycle of 12 h light and
12 h darkness per day. Rats (~200 g, Wistar CRL:WI BR) were dosed in-
travenously (i.v.) or orally (by gavage) with a single dose of 14C-labeled
test compound. Rats which were orally dosed were fasted for ~18 h
prior to and ~4 h after dose administration; otherwise, all animals
were allowed free access to standard pelleted laboratory animal diet
(Altromin, code VRF 1, Lage, Germany). Tap-water was provided ad
libitum throughout the study for all animals. In themass-balance groups
in which the animals were housed inmetabolism cages, urine and feces
were collected pre-dose and in 0–6, 6–12, 12–24, 24–48, 48–72 and
72–96 h intervals. In the toxicokinetic groups, blood was sampled alter-
nately from two rats per timepoint at 0.25, 0.5, 1, 4, 8 and 24h after dos-
ing. Remaining plasmawas pooled per group, and themetabolite proﬁle
in these pooled samples was investigated. Animals were euthanized
72 h or 96 h after dose administration, and several tissues and organs
were collected. Total radioactivity in urine, feces, tissues and organs
was determined using liquid scintillation counting. Selected urine and
feces samples were pooled per group, and the metabolite proﬁle in
these pooled samples was investigated. Samples were collected, ex-
tracted and analyzed by LC–MS/MS.
Oral absorption of total radiolabelledmaterial (i.e. parent compound
andmetabolites) was calculated twoways, using urine and plasma data
(where available). The amount in the urine, after oral and i.v. dosing,
was normalized to the total amount recovered (in the same dosing
route) according to Eq. (2).
Normalizedamount inurine ¼ %recoveredinurine
%recoveredinurineþ%recoveredinfeces
ð2Þ
The fraction absorbedwas then calculated as thenormalized amount
of radioactivity recovered in the urine after oral administration divided
by the normalized amount recovered after i.v. administration (Eq. (3)).
Fractionabsorbed ¼ Normalizedamountinurine oralð Þ
Normalizedamount inurine i:v:ð Þ ð3Þ
This calculation assumes that the ratio of urinary excreted radioac-
tivity to systemically available radioactivity was the same for both
routes. When i.v. data were not available, the amount recovered after
Ta
bl
e
3
Te
st
ch
em
ic
al
,m
ol
ec
ul
ar
w
ei
gh
t(
of
th
e
fr
ee
ba
se
s)
,s
ol
ub
ili
ty
an
d
Lo
gP
va
lu
es
.A
ll
va
lu
es
w
er
e
ob
ta
in
ed
fr
om
th
e
re
sp
ec
ti
ve
SC
CS
op
in
io
ns
,w
it
h
th
e
ex
ce
pt
io
n
of
th
e
pK
a
va
lu
es
w
hi
ch
w
er
e
ca
lc
ul
at
ed
.
Te
st
ch
em
ic
al
CA
S
nu
m
be
r
Co
m
po
un
d
ab
br
ev
ia
ti
on
M
ol
ec
ul
ar
w
ei
gh
t
W
at
er
so
lu
bi
lit
y
(g
/l)
Lo
gP
pK
a
(c
al
cu
la
te
d*
)
Re
fe
re
nc
e
To
lu
en
e
2,
5-
di
am
in
e
61
5-
50
-9
TD
A
12
2.
17
5.
03
(2
0
°C
)
0.
74
5.
98
(M
B)
,2
.8
6(
M
B)
SC
CP
(2
00
7c
)
4-
A
m
in
o-
m
-c
re
so
l
28
35
-9
9-
6
A
M
C
12
3.
16
12
0.
51
10
.3
4(
M
A
),
5.
13
(M
B)
SC
CP
(2
00
7b
)
6-
am
in
o-
m
-c
re
so
l
28
35
-9
8-
5
A
M
P
12
3.
16
5.
9
(p
H
7.
65
,2
0
°C
)
1.
14
9.
87
(M
A
),
5.
18
(M
B)
SC
CS
(2
01
2b
)
H
yd
ro
xy
et
hy
l-
p-
ph
en
yl
en
ed
ia
m
in
e
93
84
1-
25
-9
H
PD
15
2.
18
51
.2
(p
H
2.
02
,2
0
°C
)
0.
07
14
.8
7(
M
A
),
5.
93
(M
B)
,2
.9
8(
B)
SC
CS
(2
01
0a
)
H
yd
ro
xy
et
hy
l-
3,
4-
m
et
hy
le
ne
di
ox
ya
ni
lin
e
94
15
8-
14
-2
H
M
A
18
1.
25
40
8(
pH
1.
5,
20
°C
)
b
20
(p
H
6.
0)
0.
41
2
(p
H
4.
65
,3
6
°C
)
14
.6
8(
M
A
),
5.
11
(M
B)
SC
CP
(2
00
6b
)
2,
2′
-(
(4
-A
m
in
o-
3-
ni
tr
op
he
ny
l)
im
in
o)
bi
se
th
an
ol
(H
C
re
d
N
o.
13
)
94
15
8-
13
-1
H
CR
24
1.
3
0.
19
7
(p
H
1.
7,
20
°C
)
0.
62
(p
H
7.
22
,R
T)
14
.8
4(
A
),
14
.1
6(
M
A
),
4.
55
(M
B)
,−
3.
94
(B
)
SC
CS
(2
01
0c
)
2-
ch
lo
ro
-6
-e
th
yl
am
in
o-
4-
ni
tr
op
he
no
l
13
16
57
-7
8-
8
CE
N
21
6.
62
0.
10
5
(2
2
°C
)
2.
48
(p
H
7.
5,
25
°C
)
6.
43
(M
B)
,2
.9
1(
B)
SC
CP
(2
00
7e
)
2-
am
in
o-
6-
ch
lo
ro
-4
-n
it
ro
ph
en
ol
63
58
-0
9-
4
A
CP
18
8.
57
0.
45
(2
5
°C
)
1.
80
5.
20
((
M
A
),
1.
37
(M
B)
SC
CP
(2
00
6a
)
4-
hy
dr
ox
yp
ro
py
la
m
in
o-
3-
ni
tr
op
he
no
l
92
95
2-
81
-3
H
A
P
21
2.
20
b
10
(R
T)
1.
13
(c
al
cu
la
te
d)
14
.9
7(
A
),
9.
43
(M
A
),
1.
08
(M
B)
SC
CP
(2
00
7f
)
1-
(2
-H
yd
ro
xy
et
hy
l)
am
in
o-
2-
ni
tr
o-
4-
tr
iﬂ
uo
rm
et
hy
lb
en
ze
ne
(H
C
ye
llo
w
N
o.
13
)
10
44
2-
83
-8
H
CY
25
0.
18
0.
50
6
(p
H
6.
5–
7.
1,
23
°C
)
2.
54
(p
H
6.
5–
7.
1,
23
°C
)
14
.5
4(
M
A
),
−
3.
80
(M
B)
SC
CS
(2
01
0b
)
4-
A
m
in
o-
2-
hy
dr
ox
yt
ol
ue
ne
28
35
-9
5-
2
A
H
T
12
3.
16
4.
11
−
0.
53
(p
H
7.
2,
RT
)
10
.3
6(
M
A
),
4.
74
(M
B)
SC
CP
(2
00
7d
)
1-
H
yd
ro
xy
et
hy
l4
,5
-d
ia
m
in
o
py
ra
zo
le
15
56
01
-3
0-
2
H
D
A
P
14
2.
1
66
6
(2
0
°C
)
−
1.
75
(p
H
7.
0,
30
°C
)
14
.3
9(
M
A
),
5.
40
(M
B)
,−
0.
45
(B
),−
5.
94
(B
)
SC
CP
(2
00
7a
)
2-
A
m
in
o-
5-
et
hy
lp
he
no
l
14
98
61
-2
2-
3
A
EP
13
7.
24
42
8
(2
0
°C
,p
H
1.
42
)
1.
37
(p
H
7.
0)
9.
86
(M
A
),
5.
23
(M
B)
SC
CS
(2
01
2a
)
3-
((
9,
10
-D
ih
yd
ro
-9
,1
0-
di
ox
o-
4-
(m
et
hy
la
m
in
o)
-1
-a
nt
hr
ac
en
yl
)
am
in
o)
-N
,N
-d
im
et
hy
l-
N
-p
ro
py
l-
1-
Pr
op
an
am
in
iu
m
50
24
53
-6
1-
4
A
PB
38
0.
5
21
8
(p
H
5.
6,
20
°C
)
2.
44
(p
H
6.
0,
RT
)
4.
23
(M
B)
,−
1.
50
(M
B)
SC
CS
(2
01
2c
)
RT
=
Ro
om
te
m
pe
ra
tu
re
,N
D
=
no
td
et
er
m
in
ed
,*
ca
lc
ul
at
ed
us
in
g
A
CD
V
er
12
.0
,A
=
A
ci
d,
B
=
Ba
si
c,
M
A
=
M
os
tl
y
A
ci
d,
M
B
=
M
os
tl
y
Ba
si
c.
5C. Obringer et al. / Toxicology in Vitro 32 (2016) 1–7i.v. administration was assumed to be 100% (Table 2, Column 6 - % Oral
Absorption – Urine).
When plasma data was used, the fraction absorbed was calculated
by dividing the dose normalized 14C area under the curve (AUC) after
oral administration by the dose normalized 14C AUC after i.v. adminis-
tration of the radiolabelled compound (Table 2, Column 6 - % Oral Ab-
sorption – Plasma).
3. Results and discussion
Caco-2 cells have been used for decades, most prevalently in the
pharmaceutical industry, to predict the intestinal absorption of com-
pounds (low, moderate, or high), and when used in combination with
other parameters, such as solubility, this model has been shown to
have a good predictive capacity (Thomas et al., 2008). Papp values for a
particular compound can often vary signiﬁcantly from lab to lab, and
even somewhat from experiment to experiment. For this reason, labs
will often categorize or rank compounds as having low, moderate, or
high permeability based on their own historical data. We have histori-
cally used the established ranges of in vitro permeability values to pre-
dict the % absorbed (as a percentage of propranolol Papp): Low = 0 to
≈20%; Moderate =≈20 to≈60%; and High =≈60% and higher.
We have compared the in vitro Caco-2 data for 14 hair dyes (Table 1;
Fig. 2A) to the in vivo absorption properties for those same 14 hair dyes
(Table 2; Fig. 2B) and found a good correlation. The Papp values for the
14 hair dye ingredients, together with the concurrent reference controls
are shown in Table 1. Comparison of the Papp values of the hair dyes to
the values determined for propranolol in the same study is presented
in Table 1, column 6 and Fig. 2A. The reference control chemicals for
low and high absorption (Table 1, columns 3, 4 and 5) conﬁrmed that
the Caco-2 cell monolayers used in these studies exhibited tight junc-
tions (mean Papp values from all experiments for vinblastine and ranit-
idine were 0.19 × 10−6 and 0.49 × 10−6 cm/s, respectively) and also
allowed the rapid permeation of the highly absorbed compound, pro-
pranolol (41.5 × 10−6 cm/s).
Of the 14 compounds, 11 compounds (TDA, AHT, AMC, AMP, HPD,
HMA, HDAP, CEN, ACP, HAP, and HCY) exhibited moderate to high per-
meability in both the Caco-2 assay and the in vivo ADME study. Several
compounds exhibited a Caco-2 permeability of 100% with a somewhat
lower in vivo permeability (67–99%); however, this is still considered
to be a good prediction of the permeability. Similarly, HDAP exhibited
a relatively high in vivo permeability (77%) with a more moderate
Caco-2 permeability (64% of propranolol Papp), but this is still consid-
ered predictive as both are above 60%, which typically indicates a
good (moderate to high) absorption in vivo.
The remaining three compounds (APB, HCR, and AEP) exhibited a
different in vitro/in vivo absorption characteristic than the high/high
characteristic listed above. APB exhibited a very low in vitro Caco-2 per-
meability (3.7% of propranolol Papp) and a very low in vivo absorption
(5%). HCR exhibited a high Caco-2 permeability (100% of propranolol
Papp) with a moderate in vivo permeability (46%). AEP exhibited low
Caco-2 permeability (23% of propranolol Papp) with a high in vivo
permeability (100%).
It has been well established that physicochemical properties of a
chemical can determine the extent of oral absorption. Lipinski's
“rule-of-ﬁve” classiﬁes intestinal absorption using a number of descrip-
tors, including the LogP (Lipinski et al., 2001). APB has a LogP of 2.44
(Table 3), which being lower than the guideline of 5, indicates it should
be lipophilic enough to pass into the lipid membranes, and therefore,
should have good oral absorption. However, the predicted andmeasured
intestinal absorption in Caco-2 cells and rats was much lower than the
other hair dye ingredients. The Papp for APB was 1.47 × 10−6 cm/s,
which was much lower than the corresponding Papp for propranolol in
the same study (39.5 × 10−6 cm/s): 3.7% absorbed. The low Papp value
for APB was reﬂected in the in vivo studies in which the oral absorption
was only 5–11% (Table 2 and Fig. 2B). Low permeability results for some
6 C. Obringer et al. / Toxicology in Vitro 32 (2016) 1–7compounds are caused by low solubility, rather than a low permeability
per se (Hoppe et al., 2014). However, we excluded this possibility be-
cause the concentrations usedwerewell below themaximum solubility
of APB in water (Table 3) and DMSO (N50 g/l (SCCS, 2012c)). The low
absorption of APB may be due to the action of an efﬂux pump, such as
P-glycoprotein (P-gp). P-gp mediates the efﬂux of substrates and inﬂu-
ences their absorption, distribution and elimination, aswell as function-
ing as a biochemical barrier for the entry of drugs across the intestine
(Staud et al., 2010). In the presently reported studies, only the apical
to basolateral transport was evaluated, which would not indicate if
P-gp was active against the absorption of a particular compound.
Evaluating the basolateral to apical transport would have provided
such information; however, the effect of efﬂux transporters was not
the main purpose of these Caco-2 studies and therefore, the B to A ab-
sorption was not included in the study design.
The Papp value for HCR in the Caco-2modelwas higher than the pro-
pranolol Papp, indicating it should be well absorbed in vivo. The in vivo
absorption was obtained using only oral data (no i.v. data available),
which showed only 45% excreted in the urine. From this data, we
know that at least 45% was absorbed, but in reality may have been
higher. Excretion after an intravenous dose would have allowed a true
absorption to have been determined.
Early studies testing AHT, AEP and APB were performed with the
apical medium at pH of 7.4. The extent of ionization is important in
determining the drug dissolution rate and passive permeability across
the intestinal tract. The pH at the absorption site has been described
as a potential factor affecting the dissolution and absorption of various
ionizable drug molecules (DeSesso and Jacobson, 2001). Boisset found
that when the pH of the apical medium was lowered from 7.4 to 6.5 in
the Caco-2 assay there was an increase in permeability of the ionizable
compounds tested (Boisset et al., 2000). However, the pH of the apical
medium was not considered to affect the outcome of the assay since
the % ionization of these dye molecules is essentially the same at
pH 7.4 and 6.5 (Table 4). Subsequent experiments utilized an apical
pH of 6.5 to better reﬂect the acid conditions of parts of the gastrointes-
tinal tract.
The Papp value of AEP (8.9 × 10−6 cm/s)was signiﬁcantly lower than
the Papp value for propranolol (38.3 × 10−6 cm/s): 23% absorbed. How-
ever, the in vivo absorption of AEP was 100%. The discrepancy between
the in vitro and in vivo results may be due to the low recovery of this
compound in the Caco-2 assay. In the Caco-2 assay, approximately
20% of the compound was recovered while in the in vivo assay the
recovery was greater than 95%. The Caco-2 assay was repeated, with a
similar low recovery, showing reproducibility. Low recovery may be a
result of a number of factors, such as poor solubility, non-speciﬁc bind-
ing of the compound to the plate and/or support membrane, limited
metabolism by the Caco-2 cells (Pfrunder et al., 2003) or accumulationTable 4
Effect of pH on the amount of APB, AHT, and AEP ionized.
Test chemical % Ionized at pH 6.5
APB
3-((9,10-Dihydro-9,10-dioxo-4-(methylamino)-1-anthracenyl)
amino)-N,N-dimethyl-N-propyl-1-Propanaminium
CAS 502453-61-4
99.4% (contains only one
0.6% (contains two positiv
and one from the methyl
AHT
4-Amino-2-hydroxytoluene
CAS 2835-95-2
0.2% (contains one posit
AEP
2-Amino-5-ethylphenol
CAS 149861-22-3
4.9% (contains one posit
All ionization fractions were determined using the Henderson–Hasselbalch equation with pr
values).of the compound in the cell monolayer. We ruled out poor solubility
since this compound was highly soluble at the concentration tested
(Table 3). Additional studies would be needed to determine if AEP is
accumulating in the Caco-2 cells or sticking to the plate/membrane
(non-speciﬁc binding).4. Conclusions
We have compared the in vitro and in vivo intestinal absorption
properties of 14 hair dyes to conﬁrm whether non-animal models can
be used as alternatives to in vivo toxicokinetic studies as part of the
safety assessment of these compounds. Overall, there was a good
in vitro:in vivo correlation of the intestinal absorption such that
this model identiﬁed compounds that were either well absorbed or
very poorly absorbed. Of the dyes tested, the large halogenated
dye, APB, was the only one that was poorly absorbed in vivo and
in vitro, and this ﬁnding was in line with the known low oral absorp-
tion for similar types of molecules. Based on HDAP, for which both
oral and i.v. data were available, our ﬁndings suggest that moderate-
ly to highly absorbed hair dyes may also be correctly classiﬁed by
Caco-2 cells. However, more data are needed for these classes of cos-
metic ingredients to determine whether they can be used to distin-
guish between those with moderate and extensive intestinal
absorption (which has been demonstrated for drugs (Artursson
and Karlsson, 1991)).
In conclusion, the data supports the use of the in vitro Caco-2
model as an alternative to in vivo studies to determine intestinal ab-
sorption of chemicals with diverse chemical structures, like hair dye
molecules. When used in combination with other in vitro data using
keratinocytes, hepatocytes and skin penetration data, prediction
and mechanistic interpretation of the AME properties of cosmetic
ingredients such as hair dyes can be made without the use of ani-
mals. Additionally, the Caco-2 assay can be used to assess historical
animal data from oral dosing studies regarding applicability of the
no observed adverse effect level (NOAEL) for a new compound
i.e., to determine if it can be assumed that the bioavailability of the
new compound is similar to that of the read-across candidate
compound.Acknowledgments
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